Outlook Therapeutics (OTLK) EBT: 2015-2020
Historic EBT for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$9.9 million.
- Outlook Therapeutics' EBT rose 22.05% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$41.6 million, marking a year-over-year decrease of 9.64%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- Latest data reveals that Outlook Therapeutics reported EBT of -$9.9 million as of Q3 2020, which was down 57.85% from -$6.3 million recorded in Q2 2020.
- Outlook Therapeutics' 5-year EBT high stood at -$3.5 million for Q1 2016, and its period low was -$22.3 million during Q2 2016.
- Moreover, its 3-year median value for EBT was -$9.7 million (2018), whereas its average is -$9.8 million.
- The largest annual percentage gain for Outlook Therapeutics' EBT in the last 5 years was 76.12% (2017), contrasted with its biggest fall of 130.42% (2017).
- Outlook Therapeutics' EBT (Quarterly) stood at -$19.1 million in 2016, then spiked by 73.44% to -$5.1 million in 2017, then crashed by 92.10% to -$9.7 million in 2018, then increased by 9.86% to -$8.8 million in 2019, then rose by 22.05% to -$9.9 million in 2020.
- Its EBT was -$9.9 million in Q3 2020, compared to -$6.3 million in Q2 2020 and -$16.6 million in Q1 2020.